4D Molecular Therapeutics (FDMT) Enterprise Value (2019 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Enterprise Value for 7 consecutive years, with -$305.1 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value rose 39.22% to -$305.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$305.1 million, a 39.22% increase, with the full-year FY2024 number at -$424.9 million, down 47.41% from a year prior.
- Enterprise Value was -$305.1 million for Q3 2025 at 4D Molecular Therapeutics, down from -$293.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$161.7 million in Q3 2021 to a low of -$541.9 million in Q2 2024.
- A 5-year average of -$308.7 million and a median of -$288.2 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: tumbled 162.36% in 2024, then surged 45.89% in 2025.
- 4D Molecular Therapeutics' Enterprise Value stood at -$247.8 million in 2021, then grew by 13.81% to -$213.6 million in 2022, then plummeted by 34.97% to -$288.2 million in 2023, then tumbled by 47.41% to -$424.9 million in 2024, then rose by 28.2% to -$305.1 million in 2025.
- Per Business Quant, the three most recent readings for FDMT's Enterprise Value are -$305.1 million (Q3 2025), -$293.2 million (Q2 2025), and -$321.4 million (Q1 2025).